IL256264A - Methods of modulating cytosolic dna surveillance molecules - Google Patents

Methods of modulating cytosolic dna surveillance molecules

Info

Publication number
IL256264A
IL256264A IL256264A IL25626417A IL256264A IL 256264 A IL256264 A IL 256264A IL 256264 A IL256264 A IL 256264A IL 25626417 A IL25626417 A IL 25626417A IL 256264 A IL256264 A IL 256264A
Authority
IL
Israel
Prior art keywords
methods
cytosolic dna
dna surveillance
modulating
surveillance molecules
Prior art date
Application number
IL256264A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of IL256264A publication Critical patent/IL256264A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/58Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL256264A 2015-06-26 2017-12-12 Methods of modulating cytosolic dna surveillance molecules IL256264A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26
PCT/EP2016/064613 WO2016207314A2 (en) 2015-06-26 2016-06-23 Methods of modulating cytosolic dna surveillance molecules

Publications (1)

Publication Number Publication Date
IL256264A true IL256264A (en) 2018-02-28

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
IL256264A IL256264A (en) 2015-06-26 2017-12-12 Methods of modulating cytosolic dna surveillance molecules

Country Status (22)

Country Link
US (1) US20190233825A1 (enExample)
EP (1) EP3313376A2 (enExample)
JP (1) JP2018518511A (enExample)
KR (1) KR20180021874A (enExample)
CN (1) CN108472255A (enExample)
AR (1) AR105160A1 (enExample)
AU (1) AU2016282879A1 (enExample)
BR (1) BR112017028121A2 (enExample)
CA (1) CA2990526A1 (enExample)
CL (1) CL2017003373A1 (enExample)
CR (1) CR20180003A (enExample)
DO (1) DOP2017000313A (enExample)
HK (1) HK1256128A1 (enExample)
IL (1) IL256264A (enExample)
MX (1) MX2017017141A (enExample)
PE (1) PE20181208A1 (enExample)
PH (1) PH12017502413A1 (enExample)
RU (1) RU2018102915A (enExample)
SG (1) SG10201913395VA (enExample)
TW (1) TW201710509A (enExample)
UY (1) UY36756A (enExample)
WO (1) WO2016207314A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
NZ750181A (en) 2016-07-26 2023-02-24 Bayer Animal Health Gmbh Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
EP1167378B1 (en) * 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1326969B1 (en) * 2000-09-25 2009-04-15 Genetronics, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
PE20050386A1 (es) * 2003-05-29 2005-06-23 Schering Plough Ltd Composiciones farmaceuticas de florfenicol
DK1789559T3 (en) * 2004-08-13 2015-08-24 Univ Pennsylvania Methods to construct vaccines with no antibiotic resistance
JP2008511545A (ja) * 2004-08-13 2008-04-17 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性欠失dnaワクチン
PT2992899T (pt) * 2009-05-14 2020-09-21 Bayer Ip Gmbh Resposta imunitária reforçada em espécies aviárias
UY33821A (es) * 2010-12-22 2012-07-31 Bayer Animal Health Gmbh Respuesta inmune potenciada en la especie bovina
CA2834442A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
BR112016019837A2 (pt) * 2014-02-28 2017-10-17 Bayer Animal Health Gmbh plasmídeos imunoestimuladores

Also Published As

Publication number Publication date
EP3313376A2 (en) 2018-05-02
BR112017028121A2 (pt) 2018-09-04
CR20180003A (es) 2018-03-20
DOP2017000313A (es) 2018-02-28
CA2990526A1 (en) 2016-12-29
CN108472255A (zh) 2018-08-31
PH12017502413A1 (en) 2018-06-25
AU2016282879A1 (en) 2018-01-18
RU2018102915A3 (enExample) 2019-12-05
AR105160A1 (es) 2017-09-13
WO2016207314A3 (en) 2017-02-09
WO2016207314A2 (en) 2016-12-29
RU2018102915A (ru) 2019-07-29
HK1256128A1 (zh) 2019-09-13
MX2017017141A (es) 2018-03-09
US20190233825A1 (en) 2019-08-01
UY36756A (es) 2017-01-31
JP2018518511A (ja) 2018-07-12
CL2017003373A1 (es) 2018-06-29
KR20180021874A (ko) 2018-03-05
PE20181208A1 (es) 2018-07-23
TW201710509A (zh) 2017-03-16
SG10201913395VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
IL288622A (en) DNA fragmentation pattern analysis suitable clean
SG11201911430PA (en) Novel nucleic acid molecules
IL259421B (en) ror - gamma modulators
SG11201704681QA (en) Artificial nucleic acid molecules
SG10201913629VA (en) Artificial nucleic acid molecules
GB201521858D0 (en) Small molecules
GB201412659D0 (en) Molecules
EP3157573A4 (en) Alternative nucleic acid molecules and uses thereof
EP3157572A4 (en) Alternative nucleic acid molecules and uses thereof
GB201412658D0 (en) Molecules
HUE049094T2 (hu) Sejtmentes DNS kvantifikálási módszerei
HUE045086T2 (hu) Szachariddal módosított nukleinsav molekulák
ZA201605332B (en) Trpa1 modulators
PL3204749T3 (pl) Analizator cieczy
GB201516260D0 (en) System for secure analysis of datasets
IL256264A (en) Methods of modulating cytosolic dna surveillance molecules
IL256694A (en) Fusion molecules
PL3134882T3 (pl) Sposoby i układy do modulowania aktywacji samoalarmujących etykiet
IL255081B (en) Identification of nucleic acid molecules
SG11201607445QA (en) Methods of modulating wars2
PT3377106T (pt) Modulação da ciliogénese
GB201607636D0 (en) Molecules & method
GB201508443D0 (en) Methods of identifying USP-binding compounds
GB201400388D0 (en) Assessment of assemblies